ACP-001 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2009
How each study uses ACP-001 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Development codes
- ACP-001
- 1
Studies by the year they started
3 studies that test it; most in 2009 (1)
| Year | Studies |
|---|---|
| 2009 | 1 |
| 2010 | 1 |
| 2013 | 1 |
Who runs them
Industry 3 · Other 0
Ascendis Pharma A/S (3)
Studies
Open first, then newest update. How each study uses ACP-001 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 3
- A Safety, Pharmacokinetic and Pharmacodynamic Study of ACP-001 (TransCon hGH) in Adults With Growth Hormone DeficiencyCompletedPhase 2Ascendis Pharma A/SNCT01247675Written as ACP-001 (TransCon hGH)
- Safety, PK/PD (Pharmacokinetics/Pharmacodynamics) and Efficacy of ACP-001 Weekly Versus Daily hGH in Children With Growth Hormone Deficiency (GHD)CompletedPhase 2Ascendis Pharma A/SNCT01947907Written as ACP-001
- Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)CompletedPhase 1Ascendis Pharma A/SNCT01010425Written as ACP-001 (TransCon PEG hGH)